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First-line sequential high dose chemotherapy is under investigation in patients with ‘poor prognosis’ metastatic germ cell
tumours in order to improve survival. Despite the use of autologous peripheral blood stem cell transplantation and
granulocyte colony stimulating factor chemotherapy dose intensiﬁcation is associated with severe haematotoxicity including
anaemia, which may signiﬁcantly affect quality of life and tolerability of chemotherapy. This study investigates the frequency
and degree of anaemia in patients receiving ﬁrst-line sequential high dose chemotherapy for metastatic testicular cancer and
the impact of anaemia on treatment outcome. A total of 101 newly diagnosed patients with ‘poor prognosis’ metastatic
nonseminomatous germ cell tumours were treated with one cycle of standard VIP followed by three cycles of HD-VIP-
chemotherapy (etoposide, ifosfamide, cisplatin) within a large phase I/II study. Differential blood cell counts were taken prior,
during and after every cycle of chemotherapy. Additionally, the numbers of red blood cell and platelet transfusions were
recorded. Kaplan–Meier analyses were performed to correlate pre-treatment and post-treatment haemoglobin values to
response and overall survival. Forty-eight per cent of the patients were classiﬁed anaemic (haemoglobin 512 g dl
71) prior
to the start of chemotherapy. The application of sequential HD-VIP resulted in median haemoglobin nadirs between
7.8 g dl
71 (range 5.5–11.1 g dl
71) in the ﬁrst cycle and 7.6 g dl
71 (range 6.0–11.4 g dl
71) in the third cycle despite the
frequent use of red blood cell transfusions. Almost all patients (99%) had haemoglobin levels 510 g dl
71 at some timepoint
during ﬁrst-line sequential high dose chemotherapy. Overall, 97 patients received red blood cell transfusions with a median of
10 units (range 2–25) per patient during the four consecutive cycles of therapy. The time to ﬁrst transfusion was shortest in
patients with the lowest initial haemoglobin values. While there was no prediction of response or outcome by baseline
haemoglobin-levels, a signiﬁcant survival difference in favour of patients with a haemoglobin value 410.5 g dl
71 after
completion of four cycles of therapy (at leukocyte recovery after the last cycle) compared to those with haemoglobin values
510.5 g dl
71 was found with 3-year overall survival rates of 87% vs 68%, respectively (P50.05). Severe anaemia is a very
frequent side effect of sequential dose intensive therapy in patients with germ cell cancer, with almost all patients becoming
transfusion dependent. Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about
7.5–8 g dl
71 during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome
was found.
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With the use of cisplatin-based combination chemotherapy, 70–
90% of the patients with metastatic testicular cancer will be cured
(Bokemeyer et al, 1998; Hartmann et al, 1999). However, in patients
fulﬁlling ‘poor prognosis’-criteria according to the IGCCCG classi-
ﬁcation the actual 5-year survival rate is only 50–60% (IGCCCG,
1997; Sonneveld et al, 2001). A matched pair analysis has revealed
a survival beneﬁt of 15–20% for patients treated with sequential
ﬁrst-line high dose chemotherapy (HD-Ctx) plus autologous
peripheral blood stem cell transplantation (PBSCT) compared to
patients receiving standard dose chemotherapy (Bokemeyer et al,
1999). Randomised studies comparing HD-Ctx to cisplatin-based
standard dose chemotherapy are currently ongoing.
The intensiﬁcation of ﬁrst-line treatment using the dose escala-
tion of etoposide and ifosfamide is associated with a certain degree
of acute toxicities, particularly gastrointestinal side effects and
haematotoxicity. Intensive sequential HD-chemotherapy is asso-
ciated with the risk of severe neutropenia, thrombocytopenia and
anaemia despite the use of PBSC retransplantation and haemato-
C
l
i
n
i
c
a
l
Received 28 January 2002; revised 17 July 2002; accepted 8 September
2002
*Correspondence: Dr C Bokemeyer;
E-mail: carsten.bokemeyer@med.uni-tuebingen.de
British Journal of Cancer (2002) 87, 1066–1071
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.compoetic growth factors (granulocyte colony stimulating factor) (G-
CSF). There is an increasing awareness among the oncology
community that the decrease of haemoglobin (Hb) concentrations
may lead to physical and psychological consequences that adversely
effect the quality of life of cancer patients (Eguchi, 1995; Thatcher,
1998; Groopman and Itri, 1999; Ray-Coquard et al, 1999; Barrett-
Lee et al, 2000; Mercadante et al, 2000; Littlewood et al, 2001).
The cumulative risk of receiving red blood cell (RBC) transfu-
sions in patients who are treated with 4–6 cycles of
conventional cisplatin-based combination chemotherapy is
approximately 60% (Manegold, 1998; Barrett-Lee et al, 2000; Pivot
et al, 2000). RBC transfusions may be associated with adverse
effects such as viral infections, e.g. hepatitis and HIV, bacterial
and parasitic infections, haemolysis and immunologic or anaphy-
lactic reactions (Eguchi, 1995; Thatcher, 1998; Groopman and
Itri, 1999; Ray-Coquard et al, 1999; Mercadante et al, 2000).
The aim of this analysis was to describe the frequency and
degree of anaemia in patients undergoing ﬁrst-line sequential
HD-chemotherapy for ‘poor prognosis’ metastatic germ cell
tumours. Additionally, the relation between haemoglobin concen-
trations and treatment outcome has been investigated.
PATIENTS AND METHODS
This study has analysed patients with metastatic testicular germ cell
tumours (GCT) undergoing ﬁrst-line high dose chemotherapy
between 1997 and 1999. All patients were treated within a multi-
centre phase I/II study of the German Testicular Cancer Study
Group in collaboration with EORTC GU-Group treatment centres
investigating sequential HD-VIP (etoposide, ifosfamide, cisplatin)
therapy with PBSCT as ﬁrst-line treatment in patients with ‘poor
prognosis’ GCT according to IGCCCG criteria (Bokemeyer et al,
1999).
Previously untreated male patients with histologically proven
nonseminomatous GCT have been included. All patients had to
fulﬁll ‘poor prognosis’ criteria according to the IGCCCG (primary
mediastinal tumour or gonadal primary tumour with non-pulmon-
ary visceral metastases or patients with ‘poor markers’ such as AFP
410000 ng ml
71 or b-HCG 450000 U ml
71 or LDH 410
normal value) (IGCCCG, 1997). Patients with impaired renal func-
tion (creatinine clearance 550 ml min
71), inadequate bone
marrow function (leukocytes 53000 ml
71 or thrombocytes
5100000 ml
71 prior to therapy), other major organ dysfunctions
unless caused by malignant disease, evidence of second malignan-
cies except basal cell skin cancer and patients aged over 60 years
were excluded. All patients had given written informed consent
prior to therapy. The study protocol had been approved by the
Ethical Committee of Tuebingen University.
Treatment included one cycle of standard dosed VIP-
chemotherapy (cisplatin 20 mg m
72 d1–5, etoposide
100 mg m
72 d1–5 and ifosfamide 1.2 g m
72 d1–5) plus G-CSF
(5 mgk g
71) to collect autologous (planned separation yield:
56610
6 CD34+ cells kg
71 bw) followed by 3 cycles of HD-VIP
chemotherapy, consisting of cisplatin 20 mg m
72 d1–5, etoposide
300 mg m
72 d1–5 and ifosfamide 2000 mg m
72 d1–5 (level 6)
or 2400 mg m
72 (level 7) every 3 weeks given with reinfusion of
PBSC at day 7 and G-CSF support from day 7 until neutrophil
recovery 41000 ml
71 for 2 consecutive days (Table 1). This regi-
men has been previously reported (Bokemeyer et al, 1999). Only
101 patients who received all four cycles of chemotherapy were
included in this retrospective evaluation.
Differential blood cell counts were taken prior to the start of
therapy, at the beginning of every new cycle of therapy and twice
weekly during chemotherapy until white blood cell counts and
platelet levels had recovered to 42000 and 450000 ml
71, respec-
tively. Anaemia was deﬁned as a Hb level 512 g dl
71. RBC
transfusions were recommended to be used in patients with a
decrease of Hb levels below 8 g dl
71 or in case of clinical symp-
toms of anaemia. When available at the participating centres,
patients received ﬁltered transfusions of erythrocytes to reduce
the transfusion of contaminated white blood cells to a minimum.
The number and days of RBC transfusions were recorded during
each cycle. Additionally, the number of patients receiving platelet
transfusions–recommended threshold of platelet counts
510000 ml
71 or signs of bleeding–were registered.
Response to therapy was evaluated by computed scans of lungs,
abdomen and–in case of cerebral metastases–of the brain as well
as by measurement of serum tumour marker concentrations of
human chorionic gonadotropin (b-HCG), alfa-fetoprotein (AFP)
and lactate dehydrogenase (LDH). Tumour status assessments were
performed prior to therapy, after the second cycle and at the end
of therapy, and the results were classiﬁed according to WHO
criteria. To compare the development of anaemia to response to
therapy and to overall survival time, the patients were divided into
separate groups according to the Hb level prior to the start of
treatment and according to the Hb nadir after therapy. Treatment
results for the groups of patients either above or below the median
Hb-value of the total group were compared. The chi-square test
was employed for group comparisons. Analyses on long term
outcome were performed using the Kaplan–Meier method with
logrank test for the groups of patients with different degrees of
anaemia.
RESULTS
One hundred and one patients with ‘poor prognosis’ metastatic
GCT treated with HD-VIP chemotherapy have been retrospectively
analysed with respect to anaemia and treatment outcome. Patient
characteristics are given in Table 2. The median age of the patients
was 30 years. The median follow-up duration since start of
chemotherapy was 41 months (range 5–78). All patients alive
had a minimum follow-up of 1 year.
The median Hb concentration prior to start of chemotherapy
was 12.2 g dl
71 (range 7.5–17.4). Fifty-three patients (52%) had
Hb levels within the normal range (512 g dl
71) and 48 patients
(48%) started treatment with Hb levels 512 g dl
71. Two patients
without any detectable bleeding presented with Hb levels
58gd l
71 at diagnosis and received RBC transfusions prior to
the start of chemotherapy. There was no microscopically detectable
bone marrow involvement by germ cell tumour cells in these two
patients (Table 3).
After completion of one cycle of standard dose and three cycles
of HD-VIP chemotherapy the median Hb level dropped to
10.4 g dl
71 (range 8.2–14.5). Overall, only three patients (3%)
did not require any RBC transfusion during the total treatment
sequence. The remaining 98 patients (97%) have been transfused
receiving a median of 10 RBC units (range 2–25). The median
Hb decrease during all treatment cycles was 2.3 g dl
71 (range
0–7.8). There was no signiﬁcant difference in the degree of anae-
mia between patients receiving the two different chemotherapy
dose levels 6 and 7 (total ifosfamide doses 10 or 12 g m
72 cycle
71,
respectively).
Following the standard dose VIP induction cycle, the median
Hb nadir was 9.6 g dl
71 (range 6.1–15.8). Only 11 patients did
not become anaemic (Hb 512 g dl
71) during the initial cycle of
standard dose chemotherapy and another 27 patients (27%)
remained at a Hb level 410 g dl
71. Twenty-seven per cent of
the patients were transfused during the ﬁrst cycle (median number
of units 2; range 2–8).
The application of the ﬁrst cycle of HD-VIP resulted in a
median Hb nadir of 7.8 g dl
71 (range 5.5–11.1). This corre-
sponded to a median Hb decrease of 2.8 g dl
71. Three patients
(3%) preserved Hb levels 410 g dl
71, none of the patients
remained at Hb values 412 g dl
71. Seventy-six patients (76%)
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After administration of the second cycle of HD-VIP Hb levels
dropped to 7.8 g dl
71 and 85% of the patients required a median
of 4 units of RBC transfusions (range 2–12). The median Hb
nadir during the third cycle of HD-VIP was 7.6 g dl
71. In this
cycle, 91% of the patients (n=91) required a median of 6 units
of RBC (range 2–13). During the second and the third cycle of
HD-VIP only one patient (1%) remained at a Hb level
410 g dl
71. In almost all patients (99%) Hb levels declined to
values 510 g dl
71 (Table 4).
The correlation of the median Hb level prior to chemotherapy
of the 98 transfused patients to the time until ﬁrst transfusion
showed a median Hb level of 10.4 g dl
71 at start (range 7.7–
17.4) in the 27 patients receiving RBC transfusion during the ﬁrst
cycle of standard chemotherapy compared to 13.9 g dl
71 (range
9.8–16.5) in six patients receiving their ﬁrst RBC transfusion in
the third cycle of high dose chemotherapy. Fifty-four patients were
transfused for the ﬁrst time during the ﬁrst cycle of high dose VIP
with a median Hb level of 11.9 g dl
71 (range 9.9–17.4) prior to
the start of therapy. During the second cycle of HD-VIP 11
patients received their ﬁrst RBC transfusion, having started
chemotherapy with a Hb level of 12.7 g dl
71 (range 7.5–15.7).
Patient characteristics with respect to sites of metastases and
chemotherapy dose levels (6 vs 7) were not signiﬁcantly different
among those groups
Forty-two of 56 patients (75%) starting chemotherapy with Hb-
levels 510.5 g dl
71 and 35 of 45 patients (77%) with Hb levels
below 10.5 g dl
71 achieved a complete or marker negative partial
remission (n.s.). Analysis of survival times was performed using
the Kaplan–Meier method revealing similar 3-year-progression
free survival rates in both groups: 76% for the group of patients
with a pretreatment Hb value 510.5 g dl
71 vs 68% for patients
with Hb levels 510.5 g dl
71 (n.s.).
Patients with low Hb-levels (510.5 g dl
71) after completion of
HD-VIP (deﬁned as timepoint at 2–3 weeks after last CT-applica-
tion but at full neutrophil recovery) had achieved a response rate
of 70%, whereas in the group of patients with higher Hb values
after treatment (410.5 g dl
71) the response rate was determined
as 85% (P=0.07). After a median follow up of 41 months since
diagnosis the calculated 3-year overall survival rates among both
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Table 1 Treatment schedule for dose intensiﬁed ﬁrst-line chemotherapy:
Treatment is repeated at 21 day intervals, all HD-chemotherapy cycles are
supported by G-CSF (5 mgk g
71) from day 7 onwards and by retransplan-
tation of 42610
6 CD34+cells kg
71 given on day 7 of each cycle (Boke-
meyer et al, 1998)
Standard dose VIP: Cisplatin 20 mg m
72 i.v. days 1–5
Etoposide 75 mg m
72 i.v. days 1–5
Ifosfamide 1200 mg m
72 i.v. days 1–5
High-dose VIP (level 6): Cisplatin 20 mg m
72 i.v. days 1–5
Etoposide 300 mg m
72 i.v. days 1–5
Ifosfamide 2000 mg m
72 i.v. days 1–5
High-dose VIP (level 7): Cisplatin 20 mg m
72 i.v. days 1–5
Etoposide 300 mg m
72 i.v. days 1–5
Ifosfamide 2400 mg m
72 i.v. days 1–5
Table 2 Patients‘ characteristics (n=101 patients). All patients had non-
seminomatous germ cell cancer and fulﬁlled the ‘poor prognosis’ criteria of
the IGCCCG (IGCCCG, 1997).
n %
Histology
Teratocarcinoma 12 12
Embryonal carcinoma 14 14
Yolk sack tumour 7 7
Chorionic-carcinoma 3 3
Mixed histology 58 58
Not further classiﬁed 7 7
Location of metastases
Retroperitoneum 78 78
Mediastinum 44 44
Lungs 67 67
Liver 26 26
Bone 11 11
CNS 9 9
Serum tumour markers at diagnosis
AFP: median 8 mgm l
71
range 2–8.954
elevation 30 30
b-HCG: median 0.1 IU ml
71
range 0.1–210.468
elevation 39 39
LDH: median 135 IU ml
71
range 120–4.725
elevation 46 46
Table 3 Haemoglobin levels prior to the start of chemotherapy (n=101
patients)
Haemoglobin level (g dl
71) n
414 15 (15%)
12–14 38 (37%)
10–12 30 (30%)
8–10 16 (16%)
58 2 (2%)
Median value: 12.2 g dl
71 (7.5–17.4 g dl
71)
Table 4 Haemoglobin nadir values (g dl
71) during sequential dose intensiﬁed chemotherapy. The 101 patients who received all four cycles of treatment
were evaluated
Induction
therapy 1st cycle of 2nd cycle of 3rd cycle of
Haemoglobin levels SD-VIP HD-VIP HD-VIP HD-VIP
Median nadir 9.6 7.8 7.8 7.6
(Range) (6.1–15.8) (5.5–11.1) (5.5–10.6) (6.0–11.4)
Median decrease 2.2 2.8 2.6 2.8
(Range) (0.2–7.0) (0.4–7.5) (0.8–6.4) (0.7–7.2)
No. of RBC units transfused 0 3 3 4
(Range) (0–8) (0–9) (0–12) (0–13)
HD=high dose chemotherapy; RBC=red blood cell transfusion; SD=standard dose; VIP=cisplatin, etoposide, ifosfamide.
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Hb after therapy vs 68% for patients with a lower Hb value after
therapy, 95% conﬁdence interval 0.1692–0.9335, P50.03) (Figure
1). The distribution of the patients tumour characteristics and
median Hb-nadirs during therapy for these two groups are given
in Table 5. The were no signiﬁcant differences.
The degree of thrombocytopenia during intensiﬁed chemother-
apy – representing another parameter describing the degree of
haematotoxicity associated with the HD-VIP regimen – was also
analysed (Table 6). After application of the standard dose VIP
chemotherapy the median platelet nadir was 78000 ml
71 (range
9000–299000 ml
71). During the three cycles of high dose VIP
chemotherapy the median platelet nadir was 12000 ml
71 (range
1000–143000 ml
71). While most patients (85%) received no plate-
let transfusions (range 0–6) during the standard dose VIP cycle,
patients were transfused at a median of 2 days (range 0–12)
during each high dose cycle. The number of patients receiving
platelet transfusions increased from 15 (15%) during standard
VIP to 97 (96%) during high dose chemotherapy.
DISCUSSION
This report describes the frequency and severity of anaemia in
patients receiving cisplatin-based ﬁrst-line sequential high dose
chemotherapy (HD-VIP) plus autologous PBSC transplantation
for the treatment of ‘poor prognosis’ metastatic testicular cancer.
Taking into account strict criteria for the deﬁnition of anaemia
(512 g dl
71) already 50% of these young male patients with
advanced metastatic germ cell cancer have been anaemic at diagno-
sis. During the ﬁrst cycle of VIP standard dose chemotherapy the
incidence of anaemia (Hb 512 g dl
-1) reached 90% and about a
quarter of patients dropped to Hb levels 510 g dl
71, indicating
the impact of standard dose cisplatin based chemotherapy for the
induction of anaemia. Summarizing data from all cycles of HD-
VIP chemotherapy the number of patients with Hb level
510 g dl
71 was 99% and the median Hb nadir value was
7.8 g dl
71 demonstrating the signiﬁcant degree of anaemia asso-
ciated with this dose intensiﬁed chemotherapy approach despite
the frequent use of RBC transfusions. The frequency of RBC trans-
fusions increased from 27% during the standard dose VIP cycle to
91% during HD-VIP. The patients who were transfused, received a
median number of 5 units of RBC transfusions in association with
each HD-VIP cycle. During the whole treatment period 97% of all
patients required RBC transfusions with a median total number of
10 RBC packs applied. The time to ﬁrst transfusion was correlated
to the Hb level prior to the start of chemotherapy with a median
Hb value of 10.4 g dl
71 for patients being transfused in the ﬁrst
cycle compared to 13.9 g dl
71 for patients who received their ﬁrst
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Figure 1 Overall survival time of patients with Hb values 4 or
510.5 g dl
71 calculated since completion of the HD-VIP-chemotherapy.
Table 6 Platelet nadir values (10
3 ml
71) during ﬁrst-line dose intensiﬁed HD-VIP chemotherapy. The 101 patients who received all four cycles of
chemotherapy were evaluated
Induction
therapy 1st cycle of 2nd cycle of 3rd cycle of
Platelet values SD-VIP HD-VIP HD-VIP HD-VIP
Median nadir 78 15 13 12
(Range) (2–299) (4–143) (4–63) (1–42)
Median decrease 278 265 315 235
(Range) (62–902) (19–1395) (85–1017) (16–862)
Number of days with platelets transfusion 0 1 1 2
(Range) (0–6) (0–6) (0–8) (0–12)
See Table 4 for abbreviations.
Table 5 Distribution of prognostic parameters amoung patients with lower (510.5 g dl
71) or higher (410.5 g dl
71) Hb levels after completion of
chemotherapy. There were no signiﬁcant differences among both groups
Hb 510.5 g dl
71 Hb 410.5 g dl
71
(n=53 patients) (n=48 patients)
Extragonadal primary tumour 11 (21%) 9 (21%)
‘Poor’ AFP 11 (21%) 8 (17%)
‘Poor’ ß-HCG 9 (17%) 9 (21%)
‘Poor LDH’ 12 (23%) 9 (21%)
Lung metastasis 38 (72%) 29 (62%)
Visceral metastasis 18 (34%) 20 (42%)
SD-VIP 1st HD-VIP 2nd HD-VIP 3rd HD-VIP SD-VIP 1st HD-VIP 2nd HD-VIP 3rd HD-VIP
Median 10.0 7.8 7.9 7.6 9.3 7.9 7.8 7.6
Hb nadir 6.1–13.2 5.5–11.1 5.5–9.2 6.0–11.4 6.7–15.8 6.5–10.5 6.4–10.6 6.0–9.8
(Range)
See Table 4 for abbreviations.
Impact of anaemia during sequential hd-chemotherapy
C Bokemeyer et al
1069
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1066–1071RBC transfusion during the last cycle. These ﬁndings indicate the
important prognostic value of the pre-treatment Hb level for the
risk of developing transfusion dependent anaemia, as reported by
other investigators (Manegold, 1998; Groopman and Itri, 1999;
Barrett-Lee et al, 2000). With the higher number of transfusions
given, the potential side effects of RBC transfusions, such as viral
infections, haemolysis, immunological or anaphylactic reactions
may contribute to the risk associated with the treatment in this
young patient population (Groopman and Itri, 1999; Mercadante
et al, 2000). This is of particular importance, since between 50%
and 80% of all patients will be cured from testicular cancer by this
dose intensiﬁed treatment approach (Bokemeyer et al, 1998;
Sonneveld et al, 2001). With a median of 10 RBC units transfused
to each patient, the impact of cisplatin-based sequential high dose
chemotherapy on erythropoiesis and the importance of therapy-
induced anaemia is clearly demonstrated. It must be kept in mind
that the RBC transfusion approach was conservative, since the
common policy to transfuse only the amount of RBC packages
absolutely necessary has led to decreased Hb concentrations in
most patients keeping them in the range between 8 and
10 g dl
71 during the total treatment period.
Recent studies in ovarian or lung cancer patients receiving
cisplatin-based chemotherapy have demonstrated that higher Hb
levels will exert a positive effect on the patients’ tolerability of
chemotherapy (Manegold, 1998; Obermair et al, 1998; Pivot et
al, 2000). Patients with low Hb-levels due to the disease itself or
due to myelotoxic chemotherapy have a worse physical and
psychological constitution and a lower capacity to compensate
for treatment toxicity. Recently, two prospective studies in oncolo-
gical patients have demonstrated a signiﬁcant effect of Hb
concentrations during chemotherapy on quality of life (Gabrilove
et al, 2001; Littlewood et al, 2001).
With their potential side effects RBC transfusions are not the
optimal solution to treat anaemia in patients undergoing
chemotherapy. The prophylactic application of recombinant
human erythropoietin (rHu-EPO) is capable of preventing anaemia
and to decrease the frequency of transfusions in patients receiving
cisplatin-based and non-platinum containing chemotherapy in
several clinical trials (Henry, 1998; Ludwig and Fritz, 1998; Thatch-
er, 1999; Adamson and Ludwig, 1999; Crawford et al, 1999;
Ponchio et al, 2000).
Recent studies have also shown a trend for improved survival
associated with higher Hb-levels due to rHu-EPO application in
solid tumour patients receiving non-platinum based chemother-
apy (Gabrilove et al, 2001; Littlewood et al, 2001). Higher Hb
levels during treatment might be beneﬁcial in terms of
chemotherapy response and improved treatment outcome.
Another trial demonstrated a correlation between Hb levels
during chemotherapy and response to therapy. This investigation
has included patients with different types of solid tumours
(Barrett-Lee et al, 2000).
In our study no correlation between the initial Hb level prior to
the start of treatment and response to and outcome of therapy
could be demonstrated, which might be explained by the relative
mild degree of anaemia initially present in the analysed cohort.
On the other hand a signiﬁcant correlation between therapy
outcome and Hb values after completion of chemotherapy was
found in this study. This signiﬁcant correlation translated into a
long-term survival beneﬁt for the group of patients with higher
Hb-levels (87% vs 68% 3-year overall survival). This ﬁnding was
not explained by different clinical characteristics of the patients
included into the two groups as shown in Table 5. Although the
present investigation is limited due to its retrospective character
these ﬁndings may stimulate further research into the association
between anaemia and outcome of chemotherapy. Interactions
may be possible on several levels such as, e.g., increased bloodﬂow
and drug delivery to the tumour in less anaemic patients or higher
effectiveness of radical generating agents in the presence of better
oxygen supply as postulated for radiotherapy (Haensgen et al,
2001). Since anaemia is a major problem in dose intensive therapy
in the young patient population with germ cell cancer the effects of
erythropoietic growth factors on the frequency of transfusions,
quality of life and potentially also on overall response to
chemotherapy should be further studied.
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